This Article Free upon publication Full Text Full Text (PDF) Data Supplement All Versions of this Article: 2/2/108    most recent CIRCOUTCOMES.108.820357v1 Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Casscells, S. W. Articles by Cottrell, L. Search for Related Content PubMed PubMed Citation Articles by Casscells, S. W. Articles by Cottrell, L. Related Collections Epidemiology Secondary prevention Related Article

Original Articles

Use of Oseltamivir After Influenza Infection Is Associated With Reduced Incidence of Recurrent Adverse Cardiovascular Outcomes Among Military Health System Beneficiaries With Prior Cardiovascular Diseases

S. Ward Casscells, MD; Elder Granger, MD, FACP, FACPE; Amii M. Kress, MPH; Andrea Linton, MS; Mohammad Madjid, MD, MSc and Linda Cottrell, BS

From Health Affairs (S.W.C.), TRICARE Management Activity (E.G.), and Health Program Analysis and Evaluation (A.M.K., A.L., L.C.), West Falls Church, Va; and Texas Heart Institute and Baylor College of Medicine (M.M.), Houston, Tex.

Correspondence to Andrea Linton, MS, TRICARE Management Activity/Health Program Analysis and Evaluation, 5111 Leesburg Pike, Suite 810, Falls Church, VA 22041-3206. E-mail andrea.linton{at}wowway.com

Received September 8, 2008; accepted January 13, 2009.

Background— Influenza infection has been associated with increased risk of adverse cardiac and cerebral vascular outcomes. Oseltamivir, a treatment for influenza, has been shown to decrease the severity of an influenza episode, but few data exist regarding its potentially protective effect against recurrent vascular outcomes among influenza patients with a history of vascular disease.

Methods and Results— Electronic healthcare service and pharmacy records for 37 482 TRICARE beneficiaries, aged 18 and older, with a coded history of cardiovascular (CV) disease and a subsequent diagnosis of influenza from October 1, 2003, through September 30, 2007, were examined. Subjects were grouped according to whether they had filled a prescription for oseltamivir within 2 days of their influenza diagnosis. The incidence of recurrent CV events within 30 days after the influenza diagnosis among oseltavmivir-treated and untreated subjects was 8.5% and 21.2%, respectively (P<0.005). Subject age was a persistent and significant contributor to the likelihood of recurrent CV outcomes. After controlling for the differences in demographics among treated and untreated cohorts using a propensity-scored logistic regression model, a statistically significant protective effect was associated with oseltamivir treatment (odds ratio, 0.417; 95% CI, 0.349 to 0.498).

Conclusions— Our findings suggests that oseltamivir treatment for influenza is associated with significant decrease in the risk of recurrent CV events in subjects with a history of CV disease. These findings merit confirmation in further prospective and controlled studies. Meanwhile, in patients with CV disease, strict adherence with current practice guidelines for prevention and treatment of influenza is recommended.

Key Words: complications • epidemiology • follow-up studies • prevention

---

 

CLINICAL PERSPECTIVE

The online-only Data Supplement is available at http://circoutcomes.ahajournals.org/cgi/content/full/CIRCOUTCOMES.108.820357/DC1.

Related Article

Use of Oseltamivir After Influenza Infection Is Associated With Reduced Incidence of Recurrent Adverse Cardiovascular Outcomes Among Military Health System Beneficiaries With Prior Cardiovascular Diseases

S. Ward Casscells, Elder Granger, Amii M. Kress, Andrea Linton, Mohammad Madjid, and Linda Cottrell
Circ Cardiovasc Qual Outcomes 2009 2: 108-115. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				N. Freemantle and M. Calvert What can we learn from observational studies of oseltamivir to treat influenza in healthy adults? BMJ, December 8, 2009; 339(dec07_2): b5248 - b5248. [Full Text]